EFG Asset Management North America Corp. Lowers Stock Position in Insulet Corporation $PODD

Key Points

• EFG Asset Management North America Corp. reduced its stake in Insulet Corporation by 16.3%, holding a total of 7,753 shares valued at approximately $2.04 million.
• Insulet's recent quarterly earnings report showed an earnings per share of $1.17, exceeding analysts' expectations and marking a 32.9% increase in revenue year-over-year.
• Analysts are bullish on Insulet, with 16 "Buy" ratings and a price target increase from $330.00 to $350.00 from Wells Fargo.

EFG Asset Management North America Corp. trimmed its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 16.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,753 shares of the medical instruments supplier's stock after selling 1,513 shares during the quarter. EFG Asset Management North America Corp.'s holdings in Insulet were worth $2,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. American Century Companies Inc. boosted its position in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment boosted its position in Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after purchasing an additional 27,408 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Insulet by 27,298.6% in the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after purchasing an additional 661,717 shares during the last quarter.

Insulet Trading Up 0.6%

NASDAQ:PODD traded up $1.96 during trading hours on Friday, reaching $348.43. 498,473 shares of the stock were exchanged, compared to its average volume of 554,308. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average of $307.55 and a two-hundred day moving average of $289.87. Insulet Corporation has a twelve month low of $211.27 and a twelve month high of $350.00. The company has a market capitalization of $24.53 billion, a price-to-earnings ratio of 105.91, a PEG ratio of 2.92 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on PODD. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research report on Tuesday, May 13th. Raymond James Financial restated an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Barclays boosted their price target on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Wells Fargo & Company boosted their price objective on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Finally, Morgan Stanley restated an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Sixteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.